Previous 10 |
The following slide deck was published by IMV Inc. in conjunction with this Read more ...
Enrollment is underway in an 85-subject Phase 2 clinical trial, DECIDE , evaluating IMV's ( IMV ) T cell-activating immunotherapy DPX-Survivac plus chemo agent cyclophosphamide in patients with advanced platinum-sensitive and platinum-resistant ovarian cancer. More news on: IMV Inc.,...
DECIDE phase 2 clinical trial amendment successfully completed with multiple sites now open for enrollment FDA provided guidance for future registration trial design and for a potential shorter regulatory pathway for developing DPX-Survivac as a monotherapy in certain ovarian ...
DARTMOUTH, Nova Scotia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will participate in the BIO CEO and Investor Conference in New York City, NY. This event will take place February 11-12, 2019...
News, Short Squeeze, Breakout and More Instantly...
GAAP Net Income of $8.3 million or $0.25 per diluted share Non-GAAP Net Income of $11.0 million or $0.33 per diluted share Declares Third Consecutive Quarterly Dividend Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, to...
IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - First Quarter 2023 Net Investment Income per Share of $0.46 ; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to ...